Novo Nordisk Commits 200 Million to Strengthen Diabetes Care

Diabetes care requires more than medicines, as healthcare systems also need sustained support for prevention, diagnosis, and treatment access.

Novo Nordisk has committed USD 200 million to the World Diabetes Foundation (WDF) over 10 years, starting in 2027 and extending through 2036.

The funding will support the foundation's efforts to strengthen diabetes prevention and care programs in low- and middle-income countries.

The long-term commitment highlights how pharmaceutical companies can contribute beyond drug development and access, supporting healthcare partnerships and programs that address the global diabetes burden.

Novo Nordisk's USD 200 Million Pledge Supports Long-Term Diabetes Care

Novo Nordisk's decade-long funding commitment will provide the World Diabetes Foundation with greater certainty to plan long-term initiatives, strengthen partnerships and expand regional and global responses to diabetes.

WDF Managing Director Leif Jensen said the pledge recognizes the foundation's 25 years of work supporting people living with diabetes and related non-communicable diseases in low- and middle-income countries.

The commitment highlights three priorities:

• Strengthening long-term diabetes prevention programs.
• Supporting healthcare partnerships across regions.
• Expanding sustainable responses to diabetes and related diseases.

Also Read: 10 GLP-1 Drugs Revolutionizing Diabetes & Obesity Treatment

Global Diabetes Burden Highlights Need for Wider Healthcare Access

The World Health Organization estimates that approximately 830 million people worldwide live with diabetes. This scale highlights the need for stronger healthcare infrastructure, particularly in low- and middle-income countries where prevention, diagnosis, and treatment access remain important priorities.

Community-level programs and local partnerships can complement pharmaceutical treatment by improving awareness, encouraging early diagnosis, and connecting patients with healthcare services.

Novo Nordisk continues to compete in the diabetes and obesity market through medicines such as Ozempic and Wegovy. However, its foundation commitment represents a broader contribution to healthcare access.

Sustained investment in prevention, partnerships, and healthcare infrastructure could help countries build more effective responses to diabetes while supporting better long-term patient outcomes.